Search
for
Sort by
Research 661–690 of 1000+
- Canadian Expert Recommendations on Safety Overview and Toxicity Management Strategies for Sacituzumab Govitecan Based on Use in Metastatic Triple-Negative Breast Cancer
- Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy
- Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm
- BAYONET trial: staged combination with encorafenib, binimetinib, plus cetuximab following encorafenib plus cetuximab for BRAF V600E-mutant metastatic colorectal cancer
- Feasibility and tolerability of eribulin-based chemotherapy versus other chemotherapy regimens for patients with metastatic triple-negative breast cancer: a single-centre retrospective study
- The efficacy of scalp-cooling system for the prevention of chemotherapy-induced hair loss in metastatic breast cancer patients treated with eribulin
- Safety and efficacy of low-dose metronomic cyclophosphamide plus vinorelbine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes.
- Inferring Spatially Resolved Transcriptomics Data from Whole Slide Images for the Assessment of Colorectal Tumor Metastasis: A Feasibility Study
- Data from A Phase Ib Study of Chemoimmunotherapy with Pegylated Liposomal Doxorubicin and Pembrolizumab in Estrogen Receptor–Positive Metastatic Breast Cancer
- A phase 1b study of chemo-immunotherapy with pegylated liposomal doxorubicin and Pembrolizumab in estrogen receptor positive metastatic breast cancer
- Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase II study
- A randomized phase II trial on the addition of dutasteride to combined androgen blockade therapy versus combined androgen blockade therapy alone in patients with advanced or metastatic salivary duct carcinoma – the DUCT study protocol
- Cell-Type-Specific Chromatin States Differentially Prime Squamous Cell Carcinoma Tumor-Initiating Cells for Epithelial to Mesenchymal Transition
- Cutaneous adverse effects of targeted therapies
- Targeting of Smoothened for therapeutic gain
- Anti-cancer properties of olive oil secoiridoid phenols: a systematic review of in vivo studies
- Liarozole—a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate
- Steroidal 5α-reductase and 17α-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases
- Paraneoplastic alopecia associated with internal malignancies in the cat
- The Comparison of In Vitro Photosensitizing Efficacy of Curcumin-Loaded Liposomes Following Photodynamic Therapy on Melanoma MUG-Mel2, Squamous Cell Carcinoma SCC-25, and Normal Keratinocyte HaCaT Cells
- Review of Scalp Alopecia due to a Clinically Unapparent or Minimally Apparent Neoplasm (SACUMAN)
- Recurrence of Pemphigus Vulgaris Associated With Interleukin 2 Therapy
- RASopathic alopecia: Hair changes associated with vemurafenib therapy
- Vitamina D y la piel. Una revisión para dermatólogos
- Gfp-Expressing Vascularization of Gelfoam® as a Rapid in Vivo Assay of Angiogenesis Stimulators and Inhibitors
- Real-World Data on Health-Related Quality of Life Assessment in Patients With Breast Cancer Receiving Subcutaneous Trastuzumab
- Prospective Case Series of Cutaneous Adverse Effects Associated With Dabrafenib and Trametinib
- Abiraterone and spironolactone in prostate cancer: a combination to avoid
- Huge Proliferating Trichilemmal Tumors of the Scalp: Report of Six Cases
- Drug safety evaluation of exemestane